Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Expenses (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Operating Expenses data on record, last reported at $7.8 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 5.89% year-over-year to $7.8 million; the TTM value through Sep 2025 reached $25.7 million, down 5.05%, while the annual FY2024 figure was $25.2 million, 21.49% down from the prior year.
  • Operating Expenses reached $7.8 million in Q3 2025 per PLX's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $11.9 million in Q1 2022 and bottomed at $4.7 million in Q2 2025.
  • Average Operating Expenses over 5 years is $8.5 million, with a median of $8.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: rose 16.19% in 2022, then plummeted 33.03% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $11.1 million in 2021, then decreased by 21.54% to $8.7 million in 2022, then fell by 16.87% to $7.2 million in 2023, then decreased by 1.68% to $7.1 million in 2024, then grew by 9.36% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $7.8 million in Q3 2025, $4.7 million in Q2 2025, and $6.1 million in Q1 2025.